Clinical trial of hepatic arterial infusion chemotherapy combined with regorafenib in the treatment of patients with liver metastasis of colorectal cancer
Objective To observe the short-term and long-term effects of hepatic artery infusion chemotherapy(HAIC)combined with regorafenib in the treatment of liver metastasis from colorectal cancer.Methods Patients with liver metastasis from colorectal cancer were reviewed.They were divided into treatment group and control group according to cohort method.The control group was treated with mFOLFOX6 HAIC chemotherapy regimen,and the experimental group was treated with 160 mg of regorafenib orally on the 1st to 21stday on the basis of the control group,28 days as a cycle.After 28 days of treatment,the short-term efficacy was evaluated.Tumor markers,liver function,long-term efficacy,and adverse drug reactions in the two groups were compared.Results There were 38 cases in the treatment group and 42 cases in the control group.The objective response rates of the treatment group and the control group were 26.32％and 9.52％;the disease control rates were 71.05％and 47.62％.After treatment,the levels of carcinoembryonic antigen in these two groups were(10.06±2.33)and(14.67±3.50)μg·L-1;the levels of carbohydrate antigen 199 in these two groups were(41.39±10.25)and(62.19±15.38)kU·L-1;the levels of carbohydrate antigen 242 in these two groups were(8.67±2.12)and(13.04±3.17)kU·L-1;the serum carbohydrate antigen 125 levels of these two groups were(36.52±9.18)and(45.22±9.01)kU·L-1.After treatment,the serum glutamic-oxalacetic transaminase levels in these two groups were(26.44±6.72)and(33.17±8.20)U·L-1;the levels of glutamic pyruvic transaminase in these two groups were(22.98±5.78)and(30.89±7.62)U·L-1.The median progression free survival time of these two groups was 3.7 and 2.7 months;the median overall survival time of these two groups was 11.7 and 9.4 months.The difference of the obove indicators between the treatment group and the control group were statistically significant(P＜0.05).The total incidence of adverse drug reactions in the treatment group and control group were 76.32％and 59.52％,with no statistically significant difference(P＞0.05).Conclusion HAIC combined with regorafenib can significantly improve the short-term efficacy in the treatment of liver metastasis from colorectal cancer,and prolong patient survival,with good clinical benefits.
国家科技期刊平台
NSTL
万方数据
维普
